Mochi Health Compounded GLP-1 Status 2026: Lawsuit, Pharmacy Changes, and Operational Update
This page tracks Mochi Health's compounding operational status — the two active legal and regulatory risk factors and their current state as of May 2026.
For the full Mochi Health review (pricing, clinical model, insurance navigation), see the Mochi Health review.
Current operational status
Mochi Health is operating. Compounded semaglutide at $99/month ($178/month including membership) and compounded tirzepatide at $199/month ($278/month including membership) are being offered to new and existing patients as of May 2026.
Mochi has not received an FDA warning letter. The platform is not facing a shutdown order.
Active Risk 1: Eli Lilly patent lawsuit
What happened: Eli Lilly filed a patent-infringement suit against Mochi Health in federal court in 2025. Lilly's claim: Mochi's compounded tirzepatide programme infringes on patents covering the tirzepatide compound (similar to the Novo Nordisk patent suit that led to Hims's settlement and market exit in March 2026).
April 2026 update: Mochi filed a motion to dismiss, arguing it does not itself make the compound (its pharmacy partners do) and that the tirzepatide patents are invalid or not applicable to compounding. The court denied the motion to dismiss. The case is proceeding to the merits phase — discovery and substantive arguments.
What this means for patients: The lawsuit does not currently affect Mochi's ability to prescribe or fulfil compounded tirzepatide. If Lilly prevails, the likely outcome is an injunction requiring Mochi to stop offering compounded tirzepatide — not a retroactive penalty against patients. No outcome has been reached. Patients who want to understand their fallback options can review cheap GLP-1 alternatives.
Novo Nordisk suit: Novo Nordisk also filed patent suits against multiple compounders in February 2026. These suits named Mochi and other providers. Hims settled; Mochi is defending.
Active Risk 2: Aequita Pharmacy suspension
What happened: Aequita Pharmacy — the Washington State-based compounding pharmacy that was Mochi's primary fulfilment partner — had its pharmacy license suspended by Washington State's PQAC in March 2025 for violations of sterile compounding standards.
Impact on Mochi: Mochi transitioned patients to alternate compounding pharmacies. This was operationally disruptive — some patients reported delays and changes in the pharmacy filling their prescriptions. The compounded product is now coming from different 503A pharmacies.
Ongoing relevance: Aequita's suspension was a state action against that specific pharmacy; it did not constitute an action against Mochi Health or its prescribing practices. But it illustrates the pharmacy-continuity risk inherent in any telehealth platform that depends on a third-party 503A pharmacy.
FDA compounding landscape context
Mochi operates under §503A(b)(1)(D) — the "significant difference" framing that allows patient-specific compounding even for commercially available drugs, if the prescriber documents a clinical reason the branded product cannot meet the patient's needs. For a full explanation of these regulatory pathways, see 503A vs 503B pharmacies explained.
The FDA has stated that products within 10% of commercial doses do not qualify as "significantly different." Mochi's legal position on this is contested by the FDA's interpretation.
The April 30, 2026 FDA proposal to permanently exclude semaglutide and tirzepatide from the 503B bulk substances list does not directly affect 503A operators. For a detailed breakdown of how compounded vs brand semaglutide compare clinically and regulatorily, see that guide. 503A is a separate legal pathway. However, broader FDA enforcement activity in the GLP-1 compounding space has targeted the "essentially copies" argument that Mochi and similar providers use. Patients weighing lower-cost options should also review the compounding glossary for definitions of key regulatory terms.
Summary status table
| Risk factor | Date of last significant event | Current status |
|---|---|---|
| Eli Lilly patent lawsuit | April 2026 (motion to dismiss denied) | Active litigation, proceeding |
| Aequita Pharmacy suspension | March 2025 | Resolved — Mochi uses alternate pharmacies |
| FDA warning letter | — | None received |
| Novo Nordisk patent suit | February 2026 (filed) | Active litigation |
| Operational status | May 2026 | Operating, accepting new patients |
We update this page when material changes occur. For the live FDA warning letter tracker (which covers all GLP-1 compounders), see FDA warning letters tracker.
Frequently asked questions
Is Mochi Health still operating in 2026?
Yes. Mochi Health is still operating and accepting new patients for compounded semaglutide and tirzepatide as of May 2026. It has not received an FDA warning letter and has not been shut down. Two active risks — the Eli Lilly patent lawsuit and the Washington State Aequita pharmacy suspension — have not resulted in operational shutdown.
What is the Eli Lilly lawsuit against Mochi Health?
Eli Lilly filed a patent-infringement lawsuit against Mochi Health in federal court in 2025, asserting that Mochi's compounded tirzepatide programme infringes on Lilly's tirzepatide patents. Mochi filed a motion to dismiss, which was denied in April 2026. The case is proceeding to the merits phase. This is not a shutdown order — it is civil patent litigation. The outcome could require Mochi to cease tirzepatide compounding if Lilly prevails.
What happened with the Aequita Pharmacy and Mochi Health?
Aequita Pharmacy — Mochi's original compounding pharmacy partner — had its license suspended by Washington State's Pharmacy Quality Assurance Commission (PQAC) in March 2025 for violations of sterile compounding standards. This forced Mochi to transition patients to alternate compounding pharmacies. Mochi continues to operate with different pharmacy partners. Aequita's suspension was a state-level action against the pharmacy, not against Mochi Health directly.
Has Mochi Health received an FDA warning letter?
No. As of May 2026, Mochi Health has not received an FDA warning letter. We verify this monthly against the FDA warning-letter database. Note that FDA warning letters are typically addressed to compounding pharmacies and manufacturers, not to the telehealth platforms that prescribe through them — so a warning letter to one of Mochi's pharmacy partners would not necessarily appear under Mochi's name.